{
    "organizations": [],
    "uuid": "60db64252c66cafa0d9d66974f13d128e026e970",
    "author": "",
    "url": "https://www.reuters.com/article/brief-genentech-phase-iii-imblaze370-stu/brief-genentech-phase-iii-imblaze370-study-did-not-meet-primary-endpoint-compared-to-regorafenib-idUSASC0A1A8",
    "ord_in_thread": 0,
    "title": "BRIEF-Genentech Phase III IMblaze370 Study Did Not Meet Primary Endpoint Compared To Regorafenib",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 10 (Reuters) -\n* GENENTECH PROVIDES UPDATE ON PHASE III STUDY OF TECENTRIQ (ATEZOLIZUMAB) AND COTELLIC (COBIMETINIB) IN PEOPLE WITH HEAVILY PRE-TREATED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER\n* GENENTECH - PHASE III IMBLAZE370 STUDY EVALUATING COMBINATION OF TECENTRIQ AND COTELLIC DID NOT MEET PRIMARY ENDPOINT OF OVERALL SURVIVAL COMPARED TO REGORAFENIB\n* GENENTECH- RESULTS FROM IMBLAZE370 SHOWED TREATMENT WITH TECENTRIQ ALONE DID NOT PROVIDE MEANINGFUL CLINICAL BENEFIT COMPARED TO REGORAFENIB Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-10T08:07:00.000+03:00",
    "crawled": "2018-05-10T08:25:28.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "genentech",
        "provides",
        "update",
        "phase",
        "iii",
        "study",
        "tecentriq",
        "atezolizumab",
        "cotellic",
        "cobimetinib",
        "people",
        "heavily",
        "locally",
        "advanced",
        "metastatic",
        "colorectal",
        "cancer",
        "genentech",
        "phase",
        "iii",
        "imblaze370",
        "study",
        "evaluating",
        "combination",
        "tecentriq",
        "cotellic",
        "meet",
        "primary",
        "endpoint",
        "overall",
        "survival",
        "compared",
        "regorafenib",
        "result",
        "imblaze370",
        "showed",
        "treatment",
        "tecentriq",
        "alone",
        "provide",
        "meaningful",
        "clinical",
        "benefit",
        "compared",
        "regorafenib",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}